Home › Funds › RA CAPITAL MANAGEMENT, L.P. › SPRY

RA CAPITAL MANAGEMENT, L.P. position in SPRY

ARS PHARMACEUTICALS INC · Health Care

RA CAPITAL MANAGEMENT, L.P. reported holding 10,860,977 shares of SPRY (ARS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$87.0M, representing 0.76% of its reported portfolio and ranking #27 among its reported holdings. RA CAPITAL MANAGEMENT, L.P. has disclosed SPRY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)10.86M sh
Reported value held$87.00M
Portfolio Weight0.76%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How RA CAPITAL MANAGEMENT, L.P.'s SPRY position evolved

RA CAPITAL MANAGEMENT, L.P. first disclosed a stake in SPRY in Q3 2023 at 9,459,678 shares (US$35.8M). The position peaked in Q2 2025 at 10,860,977 shares, worth US$189.5M. Across 12 filings, RA CAPITAL MANAGEMENT, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 10 time(s). The most recent filing (Q2 2026) shows 10,860,977 shares valued at US$87.0M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 9.46M $35.76M New
Q4 2023 9.46M $51.84M Hold
Q1 2024 10.86M $111.00M Add
Q2 2024 10.86M $92.43M Hold
Q3 2024 10.86M $157.48M Hold
Q4 2024 10.86M $114.58M Hold
Q1 2025 10.86M $136.63M Hold
Q2 2025 10.86M $189.52M Hold
Q3 2025 10.86M $109.15M Hold
Q4 2025 10.86M $126.53M Hold
Q1 2026 10.86M $87.21M Hold
Q2 2026 10.86M $87.00M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SPRY and 13F data

SPRY (ARS PHARMACEUTICALS INC) is a Health Care company. 24 other funds we track also report a position in SPRY — the largest reported positions include Rubric Capital Management LP (US$68.4M), ORBIMED ADVISORS LLC (US$66.4M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$60.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SPRY

All SPRY fund holders →

FAQ

How long has RA CAPITAL MANAGEMENT, L.P. held SPRY?

RA CAPITAL MANAGEMENT, L.P. has disclosed SPRY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is RA CAPITAL MANAGEMENT, L.P.'s current position in SPRY?

As of Q2 2026, RA CAPITAL MANAGEMENT, L.P. holds 10.86M shares of SPRY (ARS PHARMACEUTICALS INC), valued at $87.00M, representing 0.76% of its reported portfolio and ranking #27.

Has RA CAPITAL MANAGEMENT, L.P. been buying or selling SPRY?

In the latest 13F filing (Q2 2026), RA CAPITAL MANAGEMENT, L.P. held unchanged its position in SPRY. The position peaked in Q2 2025 at 10.86M shares.

Which other funds hold SPRY?

Other major institutional holders of SPRY include Rubric Capital Management LP, ORBIMED ADVISORS LLC, DEERFIELD MANAGEMENT COMPANY, L.P., among 24 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.